The investigation of the immune microenvironment unveiled that tumors with KEAP1 mutations promote an immunosuppressive macrophage phenotype both in vitro and in vivo, but triterpenoid treatment promoted anti-tumor macrophage phenotypes in vitro and decreased the expression of immunosuppressive markers in vivo, which likely contributed to the overall decrease in the tumor burden. This evidence concerns the gene KEAP1 and neoplasm.